Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01867905 · ClinicalTrials.gov registry record
Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock
A clinical trial of Septic Shock and Bacteremia, sponsored by University of British Columbia.
- Completed
- Registry status
- 330
- Enrollment target
- 7
- Study locations
NCT01867905 is a study of Septic Shock and Bacteremia that has completed, run by University of British Columbia. The registered enrollment target is 330 participants, below the 5,045-participant average among 24 other Septic Shock trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 3 states.
The verdict
NCT01867905, a study of Septic Shock and Bacteremia, has completed, sponsored by University of British Columbia.
- COMPLETED
- Registry status
- 330 participants
- Enrollment target
- 7
- Study locations
Study Summary
Sepsis is a significant cause health care expenditure and carries an extremely high rate of morbidity and mortality if not treated appropriately. From 1979 to 2000, sepsis resulted in over 10 million admissions to hospital in the United States with a mortality rate of 17.9 to 27.8 percent. In Canada, it is estimated that the incidence of sepsis from 2008-2009 was 103.3 per 100,000 per year. Advances in the multifaceted management of sepsis in recent years have resulted in improved clinical outcomes. However, the cornerstone of sepsis management relies on the prompt administration of appropriate antibiotics. Current clinical practice suggests that antibiotic administration can be delayed up to 45 minutes in order to obtain blood cultures, whose results have a profound impact on the type and duration of antimicrobial therapy. Unfortunately, this recommendation is based on very little evidence and the investigators have found that potential life-saving treatment is often delayed in order to abide by it. Furthermore, recent data suggest that mortality could be increased by approximately 5% by delaying antibiotic administration for that time period. The investigators therefore wish to organize a prospective, multi-centre trial in order to identify the effect of antibiotic administration on blood culture positivity in patients presenting with severe sepsis or septic shock. Other objectives will be to elucidate which patient factors, including age, co-morbid conditions and clinical presentation, as well as antibiotic choice will affect blood culture results. This study will be conducted in the emergency departments at St. Paul's Hospital (SPH), Vancouver General Hospital (VGH), Lion's Gate Hospital (LGH), Surrey Memorial Hospital, Montreal General Hospital (MGH), Royal Victoria Hospital (RVH) and Maricopa Integrated Health System. Patients identified for the aforementioned conditions will be treated as per routine hospital protocol. If the patient is deemed eligible for
Conditions Studied
Study Locations (7)
British Columbia
- Lions Gate Hospital - North Vancouver
- Surrey Memorial Hospital - Surrey
- Vancouver General Hospital - Vancouver
- Saint-Paul's Hospital - Vancouver
Quebec
- Montreal General Hospital - Montreal
- Royal Victoria Hospital - Montreal
Arizona
- Maricopa Integrated Health Center - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2014-03-01 |
| Est. Completion | 2019-04-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01867905
The ClinicalTrials.gov registry entry for NCT01867905 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,045-participant average among 24 other Septic Shock trials with a reported enrollment target (93% lower). The listed sponsor is University of British Columbia, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Septic Shock appearing as the primary indexed condition, and to 0 interventions.
NCT01867905 reports 7 study locations spanning 3 distinct geographic areas - top geographies include British Columbia, Quebec, Arizona.
Frequently Asked Questions
What is clinical trial NCT01867905 about?
NCT01867905 is a clinical study titled "Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock". Sepsis is a significant cause health care expenditure and carries an extremely high rate of morbidity and mortality if not treated appropriately. From 1979 to 2000, sepsis resulted in over 10 million admissions to hospital in the United States with a mortality rate of 17.9 to 27.8 percent. In Canada...
What is the current status of trial NCT01867905?
This trial is currently completed. The enrollment target is 330 participants. The study started on 2014-03-01. Estimated completion is 2019-04-10.
What conditions does trial NCT01867905 study?
This clinical trial studies the following conditions: Septic Shock, Bacteremia, Severe Sepsis.
Who is sponsoring clinical trial NCT01867905?
This trial is sponsored by University of British Columbia, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01867905 being conducted?
This trial has 7 study locations across Arizona, British Columbia, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Septic Shock
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stress Hydrocortisone In Pediatric Septic Shock
RECRUITING · Phase 3
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
-
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
RECRUITING · Phase 3
-
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
RECRUITING · NA
-
Assessment for Implementation Methods in Sepsis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.